Cargando…

The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real-world Clinical Setting

OBJECTIVE: Schizophrenia is a debilitating disease that disrupts the lives of many affected individuals and exerts a toll on the health system. Only few studies assessed once-monthly injectable formulation of paliperidone palmitate (PP-1M) and other long-acting antipsychotics in recent onset schizop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peitl, Vjekoslav, Margetić, Branka Aukst, Vidrih, Branka, Karlović, Dalibor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813319/ https://www.ncbi.nlm.nih.gov/pubmed/35078954 http://dx.doi.org/10.9758/cpn.2022.20.1.118

Ejemplares similares

S115. SYMPTOM DOMAINS IN SCHIZOPHRENIA AND GENE POLYMORPHISMS
por: Peitl, Vjekoslav, et al.
Publicado: (2018)

EIGHTY YEARS OF ELECTROCONVULSIVE THERAPY IN CROATIA AND IN SESTRE MILOSRDNICE UNIVERSITY HOSPITAL CENTRE
por: Karlović, Dalibor, et al.
Publicado: (2020)

S215. FRONTO-TEMPORAL CEREBRAL BLOOD FLOW AND COGNITIVE FUNCTIONING IN PATIENTS WITH FIRST EPISODE PSYCHOSES TREATED WITH ARIPIPRAZOLE: PRELIMINARY FINDINGS
por: Peitl, Vjekoslav, et al.
Publicado: (2020)

COGNITIVE AND PSYCHOTIC SYMPTOMS IN A PATIENT WITH INFRATENTORIAL ARACHNOID CYST: CASE REPORT
por: Škarić, Maja, et al.
Publicado: (2021)

Platelet Serotonin Concentration Is Associated with Illness Duration in Schizophrenia and Chronological Age in Depression
por: Peitl, Vjekoslav, et al.
Publicado: (2020)

Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia
por: Peitl, Vjekoslav, et al.
Publicado: (2023)

Flavonols in Action: Targeting Oxidative Stress and Neuroinflammation in Major Depressive Disorder
por: Jazvinšćak Jembrek, Maja, et al.
Publicado: (2023)

THE USE OF ELECTRORETINOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY IN PATIENTS WITH SCHIZOPHRENIA
por: Duraković, Din, et al.
Publicado: (2020)

Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID-19
por: Nadalin, Sergej, et al.
Publicado: (2021)

Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
por: Markovic, M.
Publicado: (2022)

INFLUENCE OF THE SEROTONERGIC SYSTEM POLYMORPHISM ON THE EXPRESSION OF DENTAL ANXIETY
por: Franćeski, Tanja, et al.
Publicado: (2018)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

THE ENIGMA OF LEWY BODY DEMENTIA: A CASE REPORT
por: Orlović, Ivona, et al.
Publicado: (2020)

Psychiatric Illness or Immune Dysfunction—Brain Perfusion Imaging Providing the Answer in a Case of Anti-NMDAR Encephalitis
por: Šiško Markoš, Ines, et al.
Publicado: (2022)

Association between Insertion-Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and Treatment Response to Antipsychotic Medications: A Study of Antipsychotic-Naïve First-Episode Psychosis Patients and Nonadherent Chronic Psychosis Patients
por: Nadalin, Sergej, et al.
Publicado: (2022)

The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study
por: Oh, So-Young, et al.
Publicado: (2019)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo, Rosaria, et al.
Publicado: (2019)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si, Tianmei, et al.
Publicado: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such, Pedro, et al.
Publicado: (2021)

Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
por: Oh, Jihoon, et al.
Publicado: (2023)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2017)

Clinical relevance of Paliperidone Palmitate three-month intramuscular injection formulation: an Italian Real-World, Retrospective, one-year Mirror Image Study
por: Vanzetto, S., et al.
Publicado: (2022)

A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
por: Liu, Jie, et al.
Publicado: (2022)

Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study
por: Chan, Hsue-Wei, et al.
Publicado: (2021)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study
por: Pappa, Sofia, et al.
Publicado: (2020)

S203. EFFECT OF LONG-ACTING INJECTIONS OF PALIPERIDONE PALMITATE ON CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA BASED ON ILLNESS DURATION
por: Kim, Seoyoung, et al.
Publicado: (2020)

The Effects of Combined Social Cognition and Interaction Training and Paliperidone on Early-Onset Schizophrenia
por: Li, Yichen, et al.
Publicado: (2020)

Different onset patterns of monthly paliperidone palmitate in hospitalised patient diagnosed with schizophrenia
por: Herrera-Sánchez, Javier, et al.
Publicado: (2021)

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER
por: Birnbaum, Michael, et al.
Publicado: (2008)

Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice
por: Peuskens, Joseph, et al.
Publicado: (2014)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
por: Hodgson, Richard E
Publicado: (2019)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015)

Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
por: Gutiérrez‐Rojas, Luis, et al.
Publicado: (2022)

The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data)
por: Mauri, Massimo Carlo, et al.
Publicado: (2022)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
por: García-Carmona, Juan Antonio, et al.
Publicado: (2023)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j0gpndecs9k6cflncan1d0gla3